Clinical Trial Update: Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of mipomersen as add-on therapy in high-risk hypercholesterolemia patients. Results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Heart Disease
• Hypercholesterolemia

Drugs mentioned

• Kynamro (Mipomersen) (Mipomersen)

Snippet

Sponsor: Kastle Therapeutics, LLC | Conditions: Hypercholesterolemia, Coronary Heart Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-03-20